Evidence map›Paper›PMID 32374764›Full record

ArticlePloS one2020

Long-term in vivo biocompatibility of single-walled carbon nanotubes.

Thomas V Galassi, Merav Antman-Passig, Zvi Yaari, Jose Jessurun, Robert E Schwartz, Daniel A Heller

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Biomaterials for biomarker imaging and detection.Journal of advanced research · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. High-throughput SWCNT NIR-II screening enables cell andbioRxiv : the preprint server for biology · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Near-Infrared Fluorescent Single-Walled Carbon Nanotubes for Biosensing.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Thomas V GalassiMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Merav Antman-PassigMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.ORCID 0000-0003-2102-9139
Zvi YaariMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Jose JessurunDivision of Gastroenterology and Hepatology, Department of Medicine, Weill Medical College of Cornell University, New York, New York, United States of America.
Robert E SchwartzPhysiology, Biophysics, & Systems Biology Graduate Program, Weill Cornell Medical College, Cornell University, New York, New York, United States of America.
Daniel A HellerMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Memorial Sloan Kettering Cancer Center · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor MicroenvironmentR01CA215719 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN · 2018 to 2022
$3.1M
Transient Metabolite Detection for Single-Cell Metabolomics and DiagnosticsDP2HD075698 · NICHD · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN · 2012 to 2012
$2.7M
Modeling Hepatoblastoma using pluripotent stem cell derived hepatocyte-like cellsR01CA234614 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHWARTZ, ROBERT E · 2019 to 2023
$1.9M
Renal tubule-specific nanotherapeutics for acute kidney injuryR01DK114321 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN, JAIMES, EDGAR A · 2018 to 2020
$796k
New Hepatocyte Model Systems to study Hepatitis B Virus InfectionK08DK101754 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHWARTZ, ROBERT E · 2014 to 2018
$781k
Identification of Hepatitis B Virus permissiveness factorsR03DK117252 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHWARTZ, ROBERT E · 2018 to 2019
$254k
NCATS NIH HHS UL1 TR002384NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA215719NCI NIH HHS R01 CA234614NICHD NIH HHS DP2 HD075698NIDDK NIH HHS K08 DK101754NIDDK NIH HHS R01 DK114321NIDDK NIH HHS R03 DK117252
6 · The paper itself

Abstract

Over the past two decades, measurements of carbon nanotube toxicity and biodistribution have yielded a wide range of results. Properties such as nanotube type (single-walled vs. multi-walled), purity, length, aggregation state, and functionalization, as well as route of administration, greatly affect both the biocompatibility and biodistribution of carbon nanotubes. These differences suggest that generalizable conclusions may be elusive and that studies must be material- and application-specific. Here, we assess the short- and long-term biodistribution and biocompatibility of a single-chirality DNA-encapsulated single-walled carbon nanotube complex upon intravenous administration that was previously shown to function as an in-vivo reporter of endolysosomal lipid accumulation. Regarding biodistribution and fate, we found bulk specificity to the liver and >90% signal attenuation by 14 days in mice. Using near-infrared hyperspectral microscopy to measure single nanotubes, we found low-level, long-term persistence in organs such as the heart, liver, lung, kidney, and spleen. Measurements of histology, animal weight, complete blood count; biomarkers of organ function all suggest short- and long-term biocompatibility. This work suggests that carbon nanotubes can be used as preclinical research tools in-vivo without affecting acute or long-term health.

Indexed as

NanotechnologyAnimalsBiocompatible MaterialsBiomarkersDNA, Single-StrandedEndosomesHumansLiverLungMiceNanotubes, CarbonOptical ImagingSpleenTissue DistributionBiocompatible MaterialsBiomarkersDNA, Single-StrandedNanotubes, Carbon

Identifiers

PMID32374764
PMCPMC7202660
OpenAlexW3022645129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.